Cost minimization and budget impact analysis of rituximab versus infliximab, adalimumab, etanercept and abatacept in rheumatoid arthritis from a payer perspective in Brazil

被引：0
|
作者：
Saggia, M. G. [1 ]
Santos, E. A. [1 ]
Nasciben, V [1 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70821-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [21] Meta-analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis
    Wiens, Astrid
    Venson, Rafael
    Correr, Cassyano J.
    Otuki, Michel Fleith
    Pontarolo, Roberto
    PHARMACOTHERAPY, 2010, 30 (04): : 339 - 353
  • [22] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Al Taie, A.
    Shelbaya, A.
    VALUE IN HEALTH, 2020, 23 : S16 - S17
  • [23] COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN RHEUMATOID ARTHRITIS BY ACPA STATUS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Marinheiro, P.
    Faustino, P.
    Watanabe, S.
    Lima, P.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 136 - 136
  • [24] COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE
    Gossec, L.
    Goupille, P.
    Saraux, A.
    Bregman, B.
    Boccard, E.
    Dupont, D.
    Beresniak, A.
    VALUE IN HEALTH, 2008, 11 (06) : A542 - A543
  • [25] Cost-effectiveness analysis of etanercept versus infliximab and anakinra in the treatment of rheumatoid arthritis in italy.
    Leardini, G
    Ganguly, R
    Singh, A
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S460 - S461
  • [26] Cost effectiveness analysis of etanercept (ENBREL) versus infliximab (Remicade) in the treatment of rheumatoid arthritis patients.
    Malone, DC
    Ortmeier, BG
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S95 - S95
  • [27] Comparing abatacept to Adalimumab, Etanercept and Infliximab As First Or Second Line Agents in Patients With Rheumatoid arthritis: Experience From the rhumadata® Clinical Database and Registry
    Choquette, Denis
    Sauvageau, Diane
    Bessette, Louis
    Haraoui, Boulos
    Pelletier, Jean Pierre
    Raynauld, Jean-Pierre
    Villeneuve, Edith
    Coupal, Louis
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S186 - S186
  • [28] COST-MINIMIZATION ANALYSIS OF SUBCUTANEOUS ABATACEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SPAIN
    Ariza-Ariza, R.
    van Walsem, A.
    Canal Fontcuberta, C.
    Roldan Acevedo, C.
    Betegon Nicolas, L.
    Oyagueez Martin, I
    Janssen, K.
    VALUE IN HEALTH, 2013, 16 (07) : A564 - A564
  • [29] A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
    Park, Sang Hee
    Han, Xue
    Lobo, Francis
    Nanji, Sakina
    Patel, Dipen
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 589 - 594
  • [30] Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis
    Caporali, Roberto
    Allanore, Yannick
    Alten, Rieke
    Combe, Bernard
    Durez, Patrick
    Iannone, Florenzo
    Nurmohamed, Mike T.
    Lee, Sang Joon
    Kwon, Taek Sang
    Choi, Jean Soo
    Park, Gahee
    Yoo, Dae Hyun
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (01) : 85 - 99
12345